|
| Patient | Age | Eye | NV# | Previous treatment | Initial treatment | Retreatment/cause | Change (%) of NV-structure size from baseline (=100%) | Chang (%) of NV-angio size from baseline (=100) | Flow density within structural area (FD-structure ) in % | Flow density within angio area (FD-angio) in % | Last follow-up in weeks from baseline (and from last anti-VEGF) | Comments |
| NV-structure posttreatment | NV-structure last follow-up | NV-angio posttreatment | NV-angio last follow-up | FD-Structure baseline | FD-structure posttreatment | FD-structure last follow-up | FD-angio postbaseline | FD-angio posttreatment | FD-angio last follow-up | Last clinical follow-up | Last OCTA imaging |
|
| A | 59 | Right | 1 | Treatment-naïve | 4 monthly IVT | Yes NV recurrance | −51% | −53% | −76% | −83% | 64% | 38% | 28% | 81% | 69% | 59% | 46 (0) | 46 (0) | Recurrence of NV with vitreous bleeding at week 34 was observed. Rapid regression of NV after retreatment. |
|
| A | 59 | Left | 2 | Treatment-naïve | 4 monthly IVT | Yes NV recurrance | −8% | −3% | −78% | −85% | 62% | 25% | 16% | 62% | 66% | 75% | 45 (0) | 45 (0) | Retreatment after 37 weeks due to recurrence of NV and vitreous bleeding of fellow eye. |
|
| B | 30 | Right | 3 | PRP, 3 months before baseline | 3 monthly IVT | Yes for DME | −100% | −100% | −100% | −100% | 61% | 0% | 0% | 62% | 0% | 0% | 50 (5) | 50 (5) | Complete regression after initial treatment block. At weeks 27 and 44 anti-VEGF was administered for DME. |
|
| B | 30 | Left | 4 | PRP, 10 months before baseline | 3 monthly IVT | No | +12% | −27% | −11% | +13% | 81% | 42% | 40% | 89% | 51% | 53% | 51 (42) | 51 (42) | — |
| C | 48 | Right | 5 | Treatment-naïve | 3 monthly IVT | No | +28% | +196% | −65% | −20% | 82% | 52% | 49% | 71% | 58% | 54% | 65 (53) | 19 (9) | Consistent regression of % flow in structure and % flow in flow area, inconsistent changes of structure and flow area. Stable and clinically inactive PDRP in clinical follow-up for one year after last treatment |
|
| C | 48 | Left | 6 | Treatment-naïve | 3 monthly IVT | No | −15% | −17% | −24% | −38% | 79% | 26% | 41% | 82% | 36% | 57% | 64 (53) | 23 (13) | Regression of % flow in structure and % flow in flow area, and flow area with grossly unchanged structure area. Partial recurrence in OCTA over time without clinical signs of recurrence for one year after the last treatment. |
|
| D | 49 | Left | 7 | Treatment-naïve | 3 monthly IVT | No | +16% | −6% | −32% | −34% | 44% | 30% | 41% | 48% | 38% | 45% | 63 (45) | 44 (26) | Regression of % flow in structure and % flow in flow area. Lesser regression of flow. Grossly unchanged structure area, Partial recurrence in OCTA over time without clinical signs of recurrence for 10 months after the last treatment. |
| Previously treated for DME with anti-VEGF. |
|
| E | 51 | Right | 8 | Treatment-naïve | 3 monthly IVT | No | −23% | +52% | −33% | −30% | 76% | 73% | 27% | 79% | 84% | 54% | 48 (38) | 48 (38) | Delayed reduction of % flow in structure and flow area. Earlier, but inconsistent regression of structure and flow areas. Clinically stable for 9 months after last treatment. |
|
| E | 51 | Right | 9 | Treatment-naïve | 3 monthly IVT | No | −27% | +3% | −48% | −2% | 72% | 65% | 70% | 72% | 83% | 73% | 48 (38) | 29 (19) | Initial reduction of % flow in structure area and regression of flow area, followed by inconsistent recurrence. Strong fluctuations of structure area and % flow area around the baseline value. |
|
